Alzheimer's drug that can slow disease gets backing from FDA advisers

FILE - A sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017. A closely watched Alzheimer's drug from Eli Lilly won the backing of federal health advisers on Monday, June 10, 2024, setting the stage for the treatment's expected approval for people with mild dementia caused by the brain-robbing disease. Alzheimer's drug from Eli Lilly

The FDA will make the final decision on approval later this year. If the agency agrees with the panel's recommendation, the drug, donanemab, would only be the second Alzheimer’s drug cleared in the U.S. shown to convincingly slow cognitive decline and memory problems due to Alzheimer's. The FDA approved a similar infused drug,Lilly studied its drug by grouping patients based on their levels of a brain protein, called tau, that predicts severity of cognitive problems.

In another key difference, Lilly studied taking patients off its drug when they reached very low levels of amyloid, a sticky brain plaque that's a contributor to Alzheimer's.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Alzheimer's drug that can slow disease gets backing from FDA advisersFederal health advisers have endorsed a closely watched Alzheimer’s drug from Eli Lilly for people with mild dementia.
Source: ksatnews - 🏆 442. / 53 Read more »

Lilly's Alzheimer’s drug that can slow disease gets backing from FDA advisersThe Associated Press
Source: NBCNews - 🏆 10. / 86 Read more »

Alzheimer's drug that can slow disease gets backing from FDA advisersFederal health advisers have endorsed a closely watched Alzheimer’s drug from Eli Lilly for people with mild dementia. The FDA will make the final decision on approval later this year. If the agency agrees with its advisers, the drug would only be the second Alzheimer’s drug clearly shown to slow cognitive decline due to Alzheimer’s.
Source: AP - 🏆 728. / 51 Read more »

FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Source: KSLcom - 🏆 549. / 51 Read more »